Get ready to invest! The IPO of this pharmaceutical company will open on December 21st, with a price band set at Rs 426-448 per share. Let’s dive into the details of the Innova Captab IPO.
About Innova Captab Company:
We are a unified pharmaceutical company with a significant presence in the pharmaceutical value chain in India, covering research and development, manufacturing, drug distribution, marketing, and export.
Since our establishment on a small scale in 2006, we have steadily grown. For over 15 years now, we’ve been providing services to the top 10, with a strong presence in the top 15 Indian pharmaceutical companies, currently serving 14 of them. Holding licenses like WHO-GMP, EU-GMP, and other major certifications, we manufacture products through two state-of-the-art manufacturing facilities. With our world-class manufacturing facilities and a reliable supply chain, we strive to maintain highly skilled operations.
The foundation of our company lies in our in-house Research and Development (R&D), which focuses on creating a rapidly evolving product portfolio and catering to customer attraction and retention. We take pride in having a robust team of over 1000 employees.
As a responsible corporate entity, we are committed to continuous efforts in adhering to legal compliance, ethics, and professional conduct. We prioritize quality and patient safety, covering aspects like human rights, labour and employment, health safety, and environmental, social, and governance compliance. Our commitment extends to the existence, stability, and environmental responsibility of our employees, maintaining a quality management system.
In essence, we are dedicated to maintaining high standards, both ethically and operationally, while contributing to the pharmaceutical landscape in India.
Innova Captab IPO Overview:
Integrated pharmaceutical company, Innova Captab, has set the price band for its Initial Public Offering (IPO) at Rs 426-448 per share, aiming to raise Rs 570 crores. The IPO is scheduled to open on December 21st and close on December 26th. It comprises fresh shares worth Rs 320 crores and an Offer for Sale (OFS) of 55.80 lakh equity shares by promoters and selling shareholders.
Utilization of Funds:
Of the total IPO proceeds, Rs 144.40 crore will be used for debt repayment, Rs 23.60 crore will be invested in the company’s subsidiary UML, and Rs 72 crore will be allocated for working capital requirements. Additionally, some funds will be earmarked for general corporate purposes.
Investor Categories and Reservation:
Half of the issue is reserved for Qualified Institutional Buyers (QIBs), 35% for Retail Investors, and 15% for Non-Institutional Buyers (NIBs). Investors may place bids for a minimum of 33 equity shares and, if necessary, for multiples of 33 equity shares.
Business Profile:
Innova Captab is an integrated pharmaceutical company with a presence in research and development, manufacturing, drug distribution, marketing, and export within the pharmaceutical value chain. In the financial year 2023, the company witnessed a consolidated revenue growth of 15.72%, reaching Rs 926.38 crores, compared to Rs 800.53 crores in the previous fiscal year. The profit for FY2023 increased by 6.26% to Rs 67.95 crores, up from Rs 63.95 crores in FY22.
Lead Managers and Listing:
ICICI Securities and JM Financial are the running lead managers for the IPO. The equity shares are proposed to be listed on both the BSE (Bombay Stock Exchange) and NSE (National Stock Exchange).
So, if you’re considering investing, mark your calendars for December 21st, and stay tuned for the exciting journey of Innova Captab in the stock market!
Also read: Motisons Jewellers IPO: Know Full 10 Important Details Before Subscribing
I hope you liked this information about Innova Captab IPO. if you did, then share this with your people and keep reading palpalkikhabrein.